Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Primary Myelofibrosis 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia 1Glioblastoma 1

Interventions

Cyclophosphamide 87fludarabine phosphate 86Peripheral Blood Stem Cell Transplantation 70Mycophenolic Acid 58Tacrolimus 57Busulfan 57Whole-Body Irradiation 55Antilymphocyte Serum 47Cyclosporine 46fludarabine 39Methotrexate 38Filgrastim 38Melphalan 32ruxolitinib 30Cytarabine 30Radiotherapy 27Azacitidine 23Etoposide 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Specimen Handling 15Sirolimus 15Granulocyte Colony-Stimulating Factor 15Decitabine 15Cyclosporins 14Biopsy 14Alemtuzumab 14thymoglobulin 13venetoclax 11sargramostim 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myeloproliferative Disorders × KB004 × Clear all
NCT01211691 2015-11-17

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Humanigen, Inc.

Phase 1/2 Suspended
120 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡